Comparative Features of Pleural-Based Masses in a 6-Year-Old Child
For a 6-year-old child with a large right-sided pleural-based heterogeneous mass causing rib erosion, lung collapse, and mediastinal shift, pleuropulmonary blastoma (PPB) is the most likely diagnosis given the age, location, and imaging characteristics, followed by inflammatory myofibroblastic tumor (IMT), while neuroblastoma, Ewing sarcoma, and germ cell tumor remain important but less typical differentials for this specific presentation.
Comparative Table
| Feature | Pleuropulmonary Blastoma (PPB) | Inflammatory Myofibroblastic Tumor (IMT) | Neuroblastoma | Ewing Sarcoma | Germ Cell Tumor (GCT) |
|---|---|---|---|---|---|
| Age at Presentation | Median 8 months (Type I), 35 months (Type II), 41 months (Type III) [1]; typically <6 years [2,3] | Median 9 years; children and young adults [4,5] | 50% present with localized disease; ~35% with regional spread [6] | Children, adolescents, and young adults [7] | Variable; adolescents and young adults more common |
| Clinical Presentation | Respiratory distress, chest pain, fever, weight loss [1]; may present with pneumothorax [1]; cough, recurrent infections [2] | Diverse: chest pain, dyspnea if thoracic; abdominal pain if abdominal; often painless localized mass [5] | Depends on location; paraspinal tumors may cause spinal cord compression; systemic symptoms common [6] | Chest pain, respiratory symptoms, fever [8] | Mediastinal: dyspnea, chest pain, superior vena cava syndrome |
| Radiological Features | Right-sided predominance [3]; large pleural-based heterogeneous mass with low attenuation/cystic components [2,3]; pleural effusion common [2,3]; mediastinal shift [2,3]; absence of chest wall invasion [3]; heterogeneous enhancement [2] | Heterogeneous mass; moderate progressive enhancement; necrosis and cystic degeneration possible [5]; can show chest wall invasion [5] | Paraspinal location common; vascular encasement; calcification frequent; crosses midline; epidural extension [6]; MIBG-avid [6] | Posterior or mid-posterior mediastinum [8]; unclear boundaries [8]; necrosis and cystic degeneration [8]; moderate heterogeneous enhancement [8]; rib/vertebral invasion [8]; pleural effusion [8] | Anterior mediastinum typical; well-defined; may contain fat, calcification, or fluid levels; homogeneous or heterogeneous |
| Histopathology | Type I: purely cystic [1]; Type II: mixed cystic-solid [1]; Type III: purely solid, primitive neoplasm [1]; Type Ir: cystic without malignant cells [1]; primitive blastema with malignant mesenchymal stroma [2] | Spindle cells (myofibroblasts) with inflammatory infiltrate (plasma cells, lymphocytes) [4,5]; low-grade malignancy [5] | Small round blue cells; Homer-Wright rosettes; neuroblastic differentiation | Small round blue cells; CD99+; EWSR1-FLI1 fusion (85%) [7] | Depends on subtype: seminoma, yolk sac tumor, teratoma, choriocarcinoma, embryonal carcinoma |
| Immunohistochemistry | Vimentin+; desmin variable; cytokeratin variable | ALK+ (50-60% of cases) [4]; SMA+; vimentin+; desmin variable [5] | Synaptophysin+; chromogranin+; NSE+; NB84+ | CD99+; FLI-1+; vimentin+; cytokeratin variable | AFP+ (yolk sac), β-hCG+ (choriocarcinoma), PLAP+, OCT4+ (seminoma) |
| Molecular/Genetic | DICER1 pathogenic variants (germline or somatic) [1,9,10]; biallelic DICER1 mutations [9] | ALK fusions (50-60%) [4]; NTRK fusions rare [4]; ROS1, PDGFR fusions in ALK-negative cases [4] | MYCN amplification; segmental chromosomal aberrations (1p, 11q deletions; 17q gain) [6]; ALK mutations [6] | EWSR1-FLI1 fusion (85%) [7]; EWSR1-non-ETS fusions [7] | Isochromosome 12p in germ cell tumors |
| Tumor Markers | None specific | None specific | Urine catecholamines (VMA, HVA); serum LDH, ferritin [6] | Serum LDH elevated | AFP (yolk sac tumor), β-hCG (choriocarcinoma) |
| Management | Complete surgical resection [1,9]; Type I: surgery alone (89% 5-year OS) [1]; Types II/III: aggressive chemotherapy + radiation (74% and 53% 5-year OS respectively) [1]; surveillance for DICER1 syndrome [1,9] | Complete surgical resection is cornerstone [4,5]; ALK inhibitors (crizotinib) for ALK+ tumors (>80% response) [4]; recurrence in 25% [4]; long-term surveillance [5] | Risk-stratified chemotherapy; surgery for localized disease; radiation for high-risk; MIBG therapy; immunotherapy (anti-GD2) [6] | Multiagent chemotherapy (VDC/IE regimen); surgery; radiation therapy; consider HDT/ASCT for relapsed disease [7] | Surgery; chemotherapy (BEP regimen for malignant GCT); radiation for seminoma |
| Prognosis | Type I: 89% 5-year OS [1]; Type II: 74% [1]; Type III: 53% [1]; Type Ir: 100% [1] | Favorable with complete resection [5]; 15/16 disease-free in recent series [5]; metastasis rare (<5%) [4] | Localized: >80% survival [6]; metastatic: <30% 5-year OS [6] | Localized: >80% survival; metastatic/relapsed: poor prognosis [7] | Depends on histology and stage; mature teratoma: excellent; malignant GCT: variable |
| Key Distinguishing Features | Right-sided, cystic components, no chest wall invasion, DICER1 mutation, young age (<6 years) [1,9,2,3] | ALK positivity (50-60%), inflammatory infiltrate, recurrence risk, responds to ALK inhibitors [4,5] | Paraspinal location, MIBG-avid, catecholamines elevated, crosses midline, calcification [6] | Rib/vertebral invasion, CD99+, EWSR1-FLI1 fusion, posterior mediastinum [7,8] | Anterior mediastinum, elevated AFP/β-hCG, specific histologic subtypes |
Critical Diagnostic Approach
Initial Workup Priority
For this specific presentation (6-year-old, right-sided pleural mass, rib erosion), the diagnostic algorithm should prioritize:
- Contrast-enhanced CT chest (already obtained) - assess for cystic components, chest wall invasion, pleural effusion 11, 12
- Percutaneous or surgical biopsy - obtain adequate tissue for histopathology and molecular testing 11, 12
- Molecular genetic testing - DICER1 sequencing, ALK fusion testing, EWSR1-FLI1 fusion, MYCN amplification 1, 9, 4, 6
- Tumor markers - urine catecholamines (VMA/HVA), serum AFP, β-hCG, LDH, ferritin
- MIBG scan if neuroblastoma suspected 6
- Whole-body imaging (PET-CT or MRI) for staging once diagnosis established 12, 6
Biopsy Approach
Percutaneous image-guided core biopsy is usually appropriate (rating 8/9) for pleural-based masses 11, but surgical biopsy via VATS may provide better tissue yield and allow concurrent therapeutic intervention 12. The presence of rib erosion in this case suggests an aggressive process requiring adequate tissue for comprehensive molecular analysis.
Key Pitfalls to Avoid
- Do not assume benign congenital lesion: PPB can mimic congenital pulmonary airway malformation (CPAM) 10
- Do not delay biopsy: Clinical and radiological features alone cannot definitively distinguish these entities 12
- Ensure adequate tissue: Small biopsies may be insufficient for molecular testing; coordinate with pathology for tissue allocation 12
- Test for DICER1 germline variants: If PPB confirmed, family members may need surveillance 1, 9, 10
- Consider ALK testing: Even if IMT suspected, ALK status determines targeted therapy eligibility 4, 5
Management Differences
The management diverges significantly based on final diagnosis:
- PPB: Surgical resection is primary for Type I; chemotherapy ± radiation mandatory for Types II/III 1
- IMT: Complete surgical resection alone may be curative; crizotinib for ALK+ unresectable/recurrent disease 4, 5
- Neuroblastoma: Risk-stratified multimodal therapy; surgery timing depends on resectability and risk group 6
- Ewing sarcoma: Neoadjuvant chemotherapy before surgery; radiation for inadequate margins 7
- GCT: Surgery with chemotherapy for malignant subtypes
The presence of rib erosion with a right-sided pleural mass in a 6-year-old makes PPB and Ewing sarcoma most concerning, as PPB typically lacks chest wall invasion 3 but can cause bone erosion, while Ewing sarcoma characteristically invades bone 8. IMT remains possible given the age and can show chest wall invasion 5. Neuroblastoma would be unusual for a purely pleural presentation without paraspinal origin 6.